Sterilization Equipment Market to Grow at a CAGR of 7.7% to reach USD 20.0 billion from 2021 to 2026

 


The Sterilization Equipment Market is projected to reach USD 20.0 billion by 2026 from USD 13.8 billion in 2021, at a CAGR of 7.7%. Market growth is largely driven by the rising incidence of hospital-acquired infections, growing number of surgical procedures, increasing focus on food sterilization and disinfection, growth in the pharmaceutical and biotechnology industries, and the increasing outsourcing of sterilization services.

Get Sample PDF: https://www.marketsandmarkets.com/requestsampleNew.asp?id=642

Key Market Players:

STERIS PLC (US), Getinge AB (Sweden), 3M (US), Sotera Health (US), Fortive (US), Cardinal Health (US), Metall Zug Group (Switzerland), Stryker (US), Merck KGaA (Germany), MMM Group (Germany), MATACHANA GROUP (Spain), Tuttnauer (Netherlands), Andersen Sterilizers (US), Steelco S.p.A. (Italy), Noxilizer (US), DE LAMA S.P.A. (Italy), Cosmed Group (US), C.B.M. S.r.l. Medical Equipment (Italy), E-BEAM Services, Inc. (US)

Global Sterilization Equipment Market Dynamics

DRIVER: Rising incidence of hospital-acquired infections

Hospital-acquired infections (HAIs) are a major cause of morbidity and mortality worldwide. These include central line-associated bloodstream infections, catheter-associated urinary tract infections, and ventilator-associated pneumonia. The most common bacteria associated with HAIs include C. difficile, methicillin-resistant Staphylococcus aureus (MRSA), Klebsiella, E. coli, Enterococcus, and Pseudomonas species. The growing prevalence of HAIs globally is the primary growth driver for the sterilization equipment market.

According to the Centers for Disease Control and Prevention (CDC), up to 1.7 million hospitalized patients in the US annually acquire healthcare-associated infections (HCAIs) while being treated for other health issues, and more than 98,000 of these patients (one in 17) die due to HCAIs. In addition, 32% of all HAIs in the country are urinary tract infections, 22% are surgical-site infections, 15% are lung (pneumonia) infections, and 14% are bloodstream infections. According to the US Census Bureau, the number of individuals aged 65 and above was estimated at 52.3 million in 2019; this figure is expected to increase to 83.7 million by 2050. The rising geriatric population and the increasing incidence of chronic diseases will result in increased hospitalization rates, which, in turn, will increase the occurrence of HAIs. This is expected to boost the demand for sterilization products and services for the sterilization of medical instruments and other devices.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=642

North America accounted for the largest share of the sterilization equipment market in 2020

The global sterilization equipment market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America was the largest regional market for sterilization equipment. The growing demand for sterilization technologies from the healthcare industry to minimize the occurrence of HAIs, the increasing number of surgical procedures performed, and the presence of key players in the region are the major factors supporting the growth of the sterilization equipment market in North America.

Recent Developments:

In June 2021, STERIS acquired Cantel, a global provider of infection prevention products and services, through a US subsidiary to diversify its vast portfolio of sterilization instruments and services.

In October 2020, Getinge launched the Getinge Solsus 66 steam sterilizer for hospitals and surgical instruments with increased capacity and operational reliability compared to other sterilizers.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=642

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA : 1-888-600-6441

sales@marketsandmarkets.com

Comments

Post a Comment

Popular posts from this blog

Healthcare Simulation Market Size & Share - Global Future Growth Predictions

Image
 The global healthcare simulation market is projected to reach USD 4.6 billion by 2028 from USD 2.2 billion in 2023, at a high CAGR of 15.7% during the forecast period. The expansion of this market is fueled by the increasing adoption of advanced techniques and methodologies in delivering medical education, along with restricted patient access during medical training. Nevertheless, the market's growth is anticipated to be somewhat hampered by the constrained availability of funds and incomplete replication of medical simulators. Market Size Introduction: The healthcare simulation market size represents the total valuation of products and services within the healthcare simulation industry over a specific period, typically a year. It encompasses various simulation technologies, including manikins, simulators, simulated environments, and software solutions, utilized for medical training, education, and research purposes. Understanding the market size is crucial for stakeholders as ...
Read more

Global Dental Practice Management Software Industry worth $2.3 billion By 2028

Image
 The Global Dental Practice Management Software Market in terms of revenue was estimated to be worth $1.5 billion in 2023 and is poised to reach $2.3 billion in 2028, growing at a CAGR of 8.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The rising awareness of oral hygiene and dental treatment, the increasing demand for advanced dental procedures, and the growing market for dental tourism in developing countries are major key drivers for the market. However, data privacy and security issues are the factors which may slow down market growth. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=153532396 Dental Practice Management Software Industry Dynamics Driver: Rising demand for advanced cosmetic dental procedures Cosmetic d...
Read more

Humanized Mouse and Rat Model Market worth $349 million by 2028

Image
  In the near future, the humanized mouse and rat model industry is set to undergo transformative advancements, revolutionizing biomedical research and drug development. These cutting-edge models, where mice and rats are genetically modified to possess human-like characteristics and immune systems, will play a pivotal role in bridging the gap between preclinical studies and clinical trials. Through refined genetic engineering techniques, these models will closely mimic human physiology, enabling more accurate and predictive assessments of drug safety, efficacy, and disease mechanisms. Moreover, the industry will witness the integration of advanced technologies, such as CRISPR/Cas9, to expedite the creation of customized humanized models, tailoring them to specific diseases or individual patient profiles. These advancements will spur collaboration between academia, pharmaceutical companies, and biotech firms, fostering a dynamic research ecosystem focused on targeted therapies and p...
Read more